LANGUAGE
Press Releases
Search by Year
-
19 May 2022
Closing of the acquisition of Specific Diagnostics
Marcy l’Étoile, France - 19 mai 2022 – bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has finalized the acquisition of Specific Diagnostics, a privately held U.S. b...
-
13 May 2022
bioMérieux announces the CE marking of VIDAS® tests for Chikungunya virus diagnosis
Marcy-l'Étoile, France – May 13th 2022 – bioMérieux, a world leader in the field of in vitro diagnostics, announces the CE marking of its automated tests to diagnose Chikungunya virus (CHIKV) infectio...
-
04 May 2022
bioMérieux receives De Novo FDA Authorization for its BIOFIRE® Joint Infection (JI) Panel
Marcy l’Étoile, France - bioMérieux, a world leader in the field of in vitro diagnostics, today announces that its BIOFIRE® Joint Infection (JI) Panel has received De Novo authorization from the US Fo...
-
12 Apr 2022
Specific Diagnostics acquisition
Marcy l’Étoile, France, April 12th 2022 – bioMérieux, a world leader in the field of in vitro diagnostics, announces that it has entered into an agreement to acquire Specific Diagnostics, a privately ...
-
11 Apr 2022
First-Quarter 2022 Business Review
Marcy l’Étoile (France), April 11th, 2022 – bioMérieux, a world leader in the field of in vitro diagnostics, today releases its business review for the three months ended March 31th, 2022.
-
18 Mar 2022
bioMérieux receives FDA 510(k) clearance for its VITEK® MS PRIME new MALDI-TOF mass spectrometry identification system
bioMérieux, a world leader in the field of in vitro diagnostics, announces that VITEK® MS PRIME, its new MALDI-TOF mass spectrometry identification system, has received 510(k) clearance from the U.S. ...
-
02 Mar 2022
bioMérieux – 2021 Financial Results
The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on March 1 under the chairmanship of Alexandre Mérieux and approved the audited consolidated financial st...
-
17 Feb 2022
MYACUTECASE™, a free mobile application by bioMérieux to support clinicians in decision-making and monitoring of patients using emergency and critical care diagnostics
bioMérieux, a world leader in the field of in vitro diagnostics, launches MYACUTECASETM. This mobile application, the first of a kind developed by bioMérieux, is an aid in the interpretation of VIDAS®...
-
06 Jan 2022
French multidisciplinary consortium ARPEGE awarded public funding of close to €9 million to fight antibiotic resistance
The ARPEGE project aims to develop a set of solutions to strengthen the ability of healthcare institutions to fight antibiotic resistance. The consortium, led by Antabio, has been awarded close to €9 ...
-
14 Dec 2021
Corporate Social Responsibility: bioMérieux recently received a series of official recognitions from independent third parties
bioMérieux, a world leader in the field of in vitro diagnostics, recently received a series of official recognitions for its achievements in Corporate Social Responsibility (CSR) from independent thir...